IVIS LUMINA II XR FOR OPTICAL IMAGING OF RADIOPHARMACEUTICALS

用于放射性药物光学成像的 IVIS Lumina II XR

• 批准号: 8052174
• 负责人: YUAN-CHUAN TAI
• 金额: $ 21.76万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8052174
• 关键词: Address; Biological; Biological Sciences; Bioluminescence; Categories; Charge; Communities; Development; Ensure; Faculty; Fluorescence; Funding; Generations; Growth; Image; Imaging Device; Imaging technology; Implant; Laboratory Research; Light; Monitor; Mus; Optics; Positron; Positron-Emission Tomography; Process; Radiation; Radiopharmaceuticals; Reporter; Research; Research Personnel; Resolution; Resources; Science; Signal Transduction; Speed; System; Targeted Radiotherapy; Technology; Travel; United States National Institutes of Health; Universities; Washington; design; fluorescence imaging; imaging modality; in vivo; instrument; instrumentation; luminescence; molecular imaging; multimodality; novel; optical imaging; particle; public health relevance; research study; subcutaneous; tumor; ultraviolet

DESCRIPTION (provided by applicant): Throughout the last decade, the use of bioluminescence reporter systems has seen an exponential growth in research applications. As a result, bioluminescence imaging (BLI) has become an indispensible component of molecular imaging at Washington University and throughout the world. The use of multiple imaging modalities to address biological questions is now commonplace in imaging research laboratories. In a new twist on BLI, Robertson et al. (Phys Med Biol 2009) showed that the IVIS 100 and 200 BLI scanners (which have now been replaced by the IVIS Lumina and Spectrum, respectively) could consistently detect a Cerenkov light signal from 18F and 13N nuclides. Cerenkov radiation is produced when a charged particle travels with a velocity that exceeds the speed of light through an insulating medium. Cerenkov radiation is produced in a continuous spectrum from the near ultraviolet through the visible spectrum, distributed inversely proportional to the squire of the wavelength. "Cerenkov luminescence imaging" (CLI) was described for in vivo imaging of mice with radiopharmaceuticals that emit either positron or beta minus, and demonstrated a good correlation with 18FDG PET in detecting a subcutaneous tumor implant. Independently, another group of researchers (Liu et al, PLoS One 2010) validated CLI with additional positron and beta minus emitters. We propose the purchase of an IVIS Lumina II XR (Caliper Life Sciences, Inc.), a new generation molecular imaging tool capable of detecting luminescence, fluorescence, and x-ray emissions. The introduction of concomitant x-ray imaging with bioluminescence provides an additional degree of resolution by putting the bioluminescence signal in anatomical context. Our intended use of the IVIS Lumina II XR can be separated into three general categories: 1) projects that involve CLI; 2) projects that involve BLI and fluorescence imaging for monitoring targeted radiotherapy with beta emitting radiopharmaceuticals; and 3) traditional BLI experiments. The CLI applications will focus on developing high throughput assessment of novel PET radiopharmaceuticals. Washington University has the ideal faculty and resources to more fully develop the new CLI technology. We have 8 NIH-funded users developing radiopharmaceuticals and multimodality imaging agents, and one of them (Dr. Tai) develops PET/optical instrumentation. The existing faculty, facilities and resources at WU, together with strong institutional support, will ensure that the IVIS Lumina II XR will be utilized and developed further for a new, cutting-edge technology, which will benefit WU as a university, as well as the imaging community as a whole. Public Health Relevance: Molecular imaging is a science involving non-invasive imaging of molecular processes. We propose to purchase an IVIS Lumina II XR (Caliper Life Sciences, Inc.), a new generation molecular imaging tool capable of detecting luminescence, fluorescence, and x-ray emissions. Washington University will use the instrument primarily for "Cerenkov luminescence imaging" a cutting-edge technology designed for high throughput radiopharmaceutical development.

描述（由申请人提供）：在过去的十年中，生物发光报告系统的使用在研究应用中呈指数增长。因此，生物发光成像（BLI）已成为华盛顿大学和世界各地的分子成像不可或缺的组成部分。使用多种成像方式来解决生物学问题现在在成像研究实验室中是司空见惯的。在BLI的一个新转折中，Robertson等人（Phys Med Biol 2009）表明IVIS 100和200 BLI扫描仪（现已分别被IVIS Lumina和Spectrum取代）可以始终检测到来自18 F和13 N核素的Cerenkov光信号。切伦科夫辐射是当带电粒子以超过光速的速度穿过绝缘介质时产生的。切伦科夫辐射产生于从近紫外到可见光谱的连续光谱中，其分布与波长的平方成反比。“Cerenkov发光成像”（CLI）被描述用于使用发射正电子或β-的放射性药物对小鼠进行体内成像，并在检测皮下肿瘤植入物时证明与18 FDG PET具有良好的相关性。独立地，另一组研究人员（Liu等人，PLoS One 2010）用额外的正电子和β-发射体验证了CLI。我们建议购买IVIS Lumina II XR（卡尺生命科学公司），新一代分子成像工具，能够检测发光、荧光和X射线发射。伴随的X射线成像与生物发光的引入通过将生物发光信号置于解剖学背景中来提供额外程度的分辨率。IVIS Lumina II XR的预期用途可分为三大类：1）涉及CLI的项目; 2）涉及BLI和荧光成像的项目，用于监测使用β发射放射性药物的靶向放射治疗; 3）传统BLI实验。CLI应用程序将专注于开发新型PET放射性药物的高通量评估。华盛顿大学拥有理想的师资和资源，可以更充分地开发新的CLI技术。我们有8个NIH资助的用户开发放射性药物和多模态成像剂，其中一个（Tai博士）开发PET/光学仪器。WU现有的教师，设施和资源，以及强大的机构支持，将确保IVIS Lumina II XR将被利用和进一步开发为一种新的尖端技术，这将有利于WU作为一所大学，以及整个成像社区。 公共卫生相关性：分子成像是一门涉及分子过程非侵入性成像的科学。我们建议购买IVIS Lumina II XR（Caliper Life Sciences，Inc.），新一代分子成像工具，能够检测发光、荧光和X射线发射。华盛顿大学将使用该仪器主要用于“切伦科夫发光成像”，这是一种为高通量放射性药物开发而设计的尖端技术。

项目成果

Cherenkov luminescence imaging of shallow sources in semitransparent media.

半透明介质中浅源的切伦科夫发光成像。

• DOI: 10.1117/1.jbo.24.2.026001
• 发表时间: 2019
• 期刊: Journal of biomedical optics
• 影响因子: 3.5
• 作者: Komarov,Sergey;Liu,Yongjian;Tai,Yuan-Chuan
• 通讯作者: Tai,Yuan-Chuan

Activatable probes based on distance-dependent luminescence associated with Cerenkov radiation.

• DOI: 10.1002/anie.201302564
• 发表时间: 2013-07-22
• 期刊: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
• 影响因子: 16.6
• 作者: Kotagiri, Nalinikanth;Niedzwiedzki, Dariusz M.;Ohara, Kohtaro;Achilefu, Samuel
• 通讯作者: Achilefu, Samuel

Cherenkov luminescence imaging in transparent media and the imaging of thin or shallow sources.

透明介质中的切伦科夫发光成像以及薄或浅源的成像。

• DOI: 10.1117/1.jbo.20.3.036011
• 发表时间: 2015
• 期刊: Journal of biomedical optics
• 影响因子: 3.5
• 作者: Komarov,Sergey;Zhou,Dong;Liu,Yongjian;Tai,Yuan-Chuan
• 通讯作者: Tai,Yuan-Chuan